Eledon Pharmaceuticals, Inc.
ELDN · XNASCIK 1404281fmd_09NE0D9NAQEZF47WDG6MCZJZQ0Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2026, 56 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | – | – | – | – | – | – | – | – | – |
| Research and development | 3 | 2 | 7 | 8 | 6 | 24 | 27 | 30 | 52 | 66 |
| Total operating expenses | 5 | 13 | 14 | 16 | 18 | 37 | 88 | 43 | 71 | 83 |
| Operating income | (5) | (13) | (14) | (16) | (18) | (37) | (88) | (43) | – | – |
| Interest and investment income | 0 | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (1) | 0 | (0) | 0 | 0 | 0 | 0 | 3 | 4 | 4 |
| Income before taxes | (6) | (13) | (14) | (16) | (23) | (37) | (88) | (117) | (36) | (46) |
| Income tax expense | 0 | – | – | – | (0) | (2) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (6) | – | – | – | (23) | (35) | (88) | (117) | (36) | (46) |
| Net income | (6) | (13) | (14) | (16) | (23) | (35) | (88) | (117) | (36) | (46) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | (32) | (42) |